IAVI A001
Status:Completed
Phase:I
Principal Investigator(s):Sanjay Mehendale, Nathan Clumeck & Jan van Lunzen
Objective:The purpose of this study is to determine safety and immunogenicity (ability to induce an immune response) of a novel HIV vaccine based on adeno-associated virus (AAV)
Prevention Option(s):HIV Vaccine
Study Design:Controlled, Double-blind, Randomized
Official Code:
NCT00482027
Trial Sponsors:
Children's Hospital of Philadelphia, IAVI, Nationwide Children's Hospital, Targeted Genetics Corporation
Start Date
End Date
December 31, 2003
January 31, 2007
Enrollment:80
Age range:
18 Years ↔
50 Years
Population:Cisgender Men, Cisgender Women